title: CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.
abstract: We investigated T cell immunity against hepatocellular carcinoma (HCC), and showed that both peripheral blood mononuclear cells and tumor-infiltrating lymphocytes incubated with interleukin-2 alone displayed HLA-nonrestricted but hepatic cancer-specific cytotoxicity in a majority of patients with HCC. Namely, they lysed both HCC and cholangiocellular carcinomas in an HLA-nonrestricted manner, but they did not lyse any tumors with the other histological types tested, normal hepatocytes, or the cells transfected with hepatitis C virus or MUC1 gene. These CTL lines and clones were phenotypically CD3+CD4+CD8-. These unique CTL could play important roles in T cell immunity against HCC.
authors.affiliation: Department of Immunology, Kurume University School of Medicine, Fukuoka, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Nakao
authors.forename: M
authors.initials: M
authors.lastname: Sata
authors.forename: H
authors.initials: H
authors.lastname: Saitsu
authors.forename: S
authors.initials: S
authors.lastname: Yutani
authors.forename: M
authors.initials: M
authors.lastname: Kawamoto
authors.forename: M
authors.initials: M
authors.lastname: Kojiro
authors.forename: K
authors.initials: K
authors.lastname: Itoh
mesh_terms: D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000276:immunology*; D006526:Hepatitis C / Q000150:complications / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D008113:Liver Neoplasms / Q000150:complications / Q000276:immunology*; D008213:Lymphocyte Activation; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects / Q000276:immunology*; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D007376:Interleukin-2